Better Buy: Medical Marijuana vs. CV Sciences

February 10th, 2019 by admin Leave a reply »

Many investors have jumped on the marijuana stock bandwagon. But there’s a different form of cannabis that could be an even bigger story right now. The U.S. legalization of hemp, which is cannabis that contains very low levels of psychoactive ingredient THC, has opened the door for a potentially huge hemp-cased cannabidiol (CBD) market.

Two stocks¬†that hope to become big winners in this hemp market are Medical Marijuana (NASDAQOTH:MJNA) and CV Sciences (NASDAQOTH:CVSI). CV Sciences has performed a lot better than Medical Marijuana has, with its share price skyrocketing nearly 600% last year compared with Medical Marijuana’s 50% plunge. But which of these stocks is the better pick now?

Image source: Getty Images.

The case for Medical Marijuana

Medical Marijuana became the first publicly traded cannabis company in the U.S. in 2009. The company’s name is a bit of a misnomer since Medical Marijuana doesn’t market any products made from marijuana. However, Medical Marijuana has produced and sold hemp-based products for several years.

The company markets a broad lineup of hemp-based CBD products, including dietary supplements, skin care products, and prescription medications. Medical Marijuana also sells hemp-based CBD supplements for pets and hemp animal bedding and litter products through its wholly owned Phyto Animal Health subsidiary.

While Medical Marijuana is based in the U.S., the company targets international markets as well. It operates subsidiaries in Europe, Mexico, and Brazil, where the company became the first to introduce a medical cannabis product, in 2014.

Medical Marijuana also owns significant stakes in

Article source: